Bone Marrow TransplantationTransplantation, HomologousGraft vs Host DiseaseBone MarrowWhole-Body IrradiationBone Marrow CellsLeukemiaAnemia, AplasticTransplantation ConditioningTransplantation, AutologousTransplantation ChimeraBusulfanTissue DonorsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveRecurrenceGraft SurvivalLeukocyte TransfusionHematopoietic Stem Cell TransplantationHistocompatibility TestingGraft vs Tumor EffectHistocompatibilityPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myeloid, AcuteRemission InductionRadiation ChimeraCyclophosphamideGraft vs Host ReactionLymphocyte DepletionHematologic NeoplasmsGraft vs Leukemia EffectAcute DiseaseTransplantation, IsogeneicBone and BonesLymphocyte TransfusionHepatic Veno-Occlusive DiseaseLeukemia, MyeloidImmunosuppressive AgentsBone Marrow PurgingCombined Modality TherapyMice, Inbred C57BLHematopoietic Stem CellsChimeraImmunosuppressionTreatment OutcomeT-LymphocytesMyelodysplastic SyndromesTime FactorsNuclear FamilyHematopoiesisLiver TransplantationCyclosporineTransplantation ImmunologyGraft RejectionSurvival AnalysisActuarial AnalysisHLA AntigensRetrospective StudiesCytomegalovirus InfectionsHematologic DiseasesFatal OutcomeLymphoma, Non-HodgkinMice, Inbred BALB CCytarabineSevere Combined ImmunodeficiencySurvival RateBone Marrow DiseasesAntineoplastic Combined Chemotherapy ProtocolsDisease-Free SurvivalFollow-Up StudiesKidney TransplantationPancytopeniaSpleenLeukocyte CountGranulocyte Colony-Stimulating FactorLeukemia, Myelomonocytic, AcuteAnemia, Refractory, with Excess of BlastsMethotrexateNeoplasm, ResidualStem Cell TransplantationEtoposideInfectionBone Marrow ExaminationLymphomaPrognosisMultiple MyelomaCyclosporinsFlow CytometryGanciclovirAntilymphocyte SerumImmunocompromised HostSalvage TherapyBone RemodelingImmunophenotypingCytogeneticsBone Marrow NeoplasmsLife TablesColony-Forming Units AssayMice, Inbred AKRMinor Histocompatibility AntigensPneumonia, Viral